Short Interest in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Expands By 18.7%

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 10,800 shares, a growth of 18.7% from the November 30th total of 9,100 shares. Approximately 1.7% of the company’s shares are short sold. Based on an average daily trading volume, of 18,700 shares, the short-interest ratio is presently 0.6 days.

Titan Pharmaceuticals Stock Down 3.4 %

NASDAQ:TTNP traded down $0.12 during midday trading on Monday, hitting $3.40. The stock had a trading volume of 15,480 shares, compared to its average volume of 130,737. The stock has a 50-day moving average of $3.82 and a 200 day moving average of $5.07. Titan Pharmaceuticals has a one year low of $3.12 and a one year high of $14.80.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Titan Pharmaceuticals in a research report on Friday. They issued a “sell” rating for the company.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.